Detect New infections of HIV, Hepatitis C, syphilis and Hepatitis B Feasibility of conduct

3
TUPDD0101:WILL A MULTIPLEX ASSAY DETECT NEW INFECTIONS OF HIV, SYP, HEP C AND B IN URBAN INDIA? 1.Detect New infections of HIV, Hepatitis C, syphilis and Hepatitis B 2.Feasibility of conduct 3.Diagnostic accuracy 4.Client preference POPULATIO N INTERVENT ION SETTING Hinduja National Hospital and Medical Research Center, and Sion Hospitals Mumbai, India Point of care + combined counselling+ confirmatory testing STD Clinic attendees Sion Hospital, Mumbai OBJECTIV E Mumbai Urban Poor Miriad TM test on fingerstick blood

description

TUPDD0101:Will a multiplex assay detect new infections of HIV, Syp , Hep C and B in Urban India?. Objective. Detect New infections of HIV, Hepatitis C, syphilis and Hepatitis B Feasibility of conduct Diagnostic accuracy Client preference. Intervention. Setting. Population. - PowerPoint PPT Presentation

Transcript of Detect New infections of HIV, Hepatitis C, syphilis and Hepatitis B Feasibility of conduct

Page 1: Detect New  infections  of HIV, Hepatitis C, syphilis and Hepatitis B   Feasibility  of conduct

TUPDD0101:WILL A MULTIPLEX ASSAY DETECT NEW INFECTIONS OF HIV, SYP, HEP C AND B IN URBAN INDIA?

1. Detect New infections of HIV, Hepatitis C, syphilis and Hepatitis B

2. Feasibility of conduct3. Diagnostic accuracy4. Client preference

POPULATION

INTERVENTION SETTING

Hinduja National Hospital and Medical Research Center, and Sion Hospitals Mumbai, India

Point of care + combined counselling+

confirmatory testing STD Clinic attendees

Sion Hospital, Mumbai

OBJECTIVE

Mumbai Urban Poor

MiriadTM test on fingerstick blood

Page 2: Detect New  infections  of HIV, Hepatitis C, syphilis and Hepatitis B   Feasibility  of conduct

FLOW OF PARTICIPANTS

Page 3: Detect New  infections  of HIV, Hepatitis C, syphilis and Hepatitis B   Feasibility  of conduct

CATEGORY

SENSITIVITY

SPECIFICITY

REFERENCE STANDARDIndex test statusPRELIMINARY

POSITIVE

Index test statusPRELIMINARY

NEGATIVE

HIV 100% [95%, CI: 94.8,

100]

99.7% [95%, CI: 98.3,

99.9]

ELISA (antigen+antibody) +

Western BlotELISA

HBV 13.3% [95%, CI: 6.6, 23.2]

99.3% [95%, CI: 97.6,

99.9]

HBsAg + Total anti HBc + HBV DNA HBsAg + anti-HBc

HCV 50% [95%, CI: 1.26,

98.74]

99.7% [95%, CI: 98.5,

99.9]

HCV antibody + HCV RNA

Anti HCV screening test (EIA based)

Syphilis 86.1% [95%, CI: 70.5,

95.3]

85.2% [95%, CI: 80.9,

88.8]TRUST + TPHA TPHA

RESULTSDemographics

Gender 83% males

Age (mean) 31.2 years

Sample size375 STD Clinic

attendees

NITIKA PANT PAI, MD, MPH, PhDAssistant professor

McGill University, MontrealEmail: [email protected];

Co-investigators: Dr Anjali Shetty Hinduja Dr Rachita Dhurat, Sion